Table 1.
Baseline characteristics according to treatment randomization order
| Sequence PAT-SPS (N = 25) | Sequence SPS-PAT (N = 23) | P-value | |
|---|---|---|---|
| Age (years) | 69.4 ± 16.5 | 62.8 ± 22.2 | .252 |
| Gender (men), n (%) | 18 (72.0) | 17 (73.9) | .882 |
| Ethnicity (Caucasian), n (%) | 22 (88.0) | 17 (73.9) | .575 |
| BMI (kg/m2) | 24.9 ± 4.0 | 24.9 ± 5.7 | .981 |
| Diabetes, n (%) | 10 (41.6) | 10 (45.4) | .796 |
| Smoker, n (%) | 2 (8.3) | 1 (4.5) | .603 |
| Residual diuresis, n (%) | 14 (56.0) | 9 (39.1) | .243 |
| RAAS inhibitor, n (%) | 13 (52.0) | 12 (52.1) | .990 |
| Loop diuretic, n (%) | 9 (36.0) | 7 (30.4) | .683 |
| Beta-blocker, n (%) | 12 (48.0) | 11 (47.8) | .990 |
| K+ value on first session of week 1 | 5.39 ± 0.70 | 5.04 ± 0.95 | .164 |
| K+ value on first session of week 7 | 5.40 ± 0.60 | 5.34 ± 0.72 | .769 |
| Calcium (mmol/L) | 2.30 ± 0.19 | 2.24 ± 0.19 | .353 |
| Phosphate (mmol/L) | 1.73 ± 0.48 | 1.67 ± 0.51 | .686 |
| Magnesium (mmol/L) | 0.86 ± 0.17 | 0.90 ± 0.15 | .449 |
PAT, patiromer; SPS, sodium polystyrene sulfonate; BMI, body mass index; RAAS, renin-angiotensin-aldosterone system.